Novartis to Build Seventh US Plant as Part of Major Investment Drive

Novartis continues to solidify its commitment to the United States with the announcement of a seventh major production facility. This new site in Morrisville, North Carolina, represents a significant expansion of the Swiss pharmaceutical leader's manufacturing capabilities in the US, underscoring its strategic investment of $23 billion in the region.

The state-of-the-art facility will be dedicated to producing active pharmaceutical ingredients for both traditional solid dosage forms, such as tablets and capsules, and cutting-edge RNA-based therapies. This move not only enhances Novartis's production of critical medicines for American patients but also bolsters its integrated, end-to-end manufacturing strategy within the US.

This expansion is part of a broader trend of major pharmaceutical companies increasing their domestic production in the United States, driven by various factors including supply chain resilience and market access. For Novartis, this investment signifies a long-term vision to serve the American market efficiently and reliably, ensuring access to vital treatments while contributing to the local economy in North Carolina.